Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 1 147 GBX 0.88% Market Closed
Market Cap: £9.8B

Smith & Nephew PLC
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Smith & Nephew PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Smith & Nephew PLC
LSE:SN
Net Issuance of Common Stock
-$490m
CAGR 3-Years
-48%
CAGR 5-Years
-150%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Net Issuance of Common Stock
-$4.4m
CAGR 3-Years
20%
CAGR 5-Years
37%
CAGR 10-Years
22%
EKF Diagnostics Holdings PLC
LSE:EKF
Net Issuance of Common Stock
-£5m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Net Issuance of Common Stock
£11.1m
CAGR 3-Years
-31%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Inspiration Healthcare Group PLC
LSE:IHC
Net Issuance of Common Stock
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
EMV Capital PLC
LSE:EMVC
Net Issuance of Common Stock
£1.4m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Smith & Nephew PLC
Glance View

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 111.74 GBX
Overvaluation 3%
Intrinsic Value
Price GBX1 147

See Also

What is Smith & Nephew PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
-490m USD

Based on the financial report for Dec 31, 2025, Smith & Nephew PLC's Net Issuance of Common Stock amounts to -490m USD.

What is Smith & Nephew PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-150%

The average annual Net Issuance of Common Stock growth rates for Smith & Nephew PLC have been -48% over the past three years , -150% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett